From: Antiretroviral therapy response among HIV-2 infected patients: a systematic review
Study (Author, year) | CD4 count Baseline Median [IQR] | CD4 count Month-6 Median [IQR] | CD4 count Month-12 Median [IQR] | CD4 count Month -24 Median [IQR] | Delta of CD4 count cells/mm3 | Slope of CD4 count (first period) | Slope of CD4 count (second period) | Comments |
---|---|---|---|---|---|---|---|---|
Adje-Touré, 2003 [34] | 82 [52–188] | 154 [68–275] | 163 [132–244] | NR | NR | NR | NR | NR |
Van Der Ende, 2003 [29] | 90 [10–360] | 230 [40–380] | 270 [60–410] | NR | NR | NR | NR | 13 patients (Group II) |
Mullins 2004 [39] | 134[93–205] | NR | NR | NR | NR | NR | NR | Median of CD4 count at the last visit |
327 [202–408] | ||||||||
Matheron, 2006 [40] | 136 [57–244] | 177 | 181 | 221 | M6: +53 (+10; +86) | NR | NR | At 12 months |
[98–328] | [123–290] | [133–374] |  |  |  | No PI: +40 (+18; +97) | ||
 |  |  | M12: +41 (+9; +92) |  |  |  | ||
 |  |  | M24: +62 (9; 120) |  |  | PI: (+41 (+8, +86) | ||
 |  |  |  |  |  | P (0.67) | ||
Ndour, 2006 [41] | 204 [12–1029] | NR | NR | NR | Month-12 | NR | NR | NR |
 |  |  | +200 cells/mm3 |  |  |  | ||
Drylewicz, 2008 [12] | 267 [163–381] | NR | NR | NR | NR | <2 months 25 (7; 42) cells/μl/months | >2 months-3 (-38; +32) cells/μl/year | Slope of % of CD4 count was reported |
Ruelle 2008 [42] | 226 [124–359] | NR | NR | NR | PI containing regimens: +89 cells/mm3 [-31; 323] |  | PI group 106 cells/μl/year |  |
PI sparing regimens-53 cells/mm3 [-62; 57] | Without PI-25 cells/μl/year | |||||||
Benard A, 2009 [28] | 142 [59–259] |  |  |  | M6: +71 [11–116] M12: +122 [61–159] M24 + 132 [110–275] | <3 months 24.3 (7.1; 41.4) cells/μl/months | >3 months +8.50 (+5.3; +11.7) cells/μl/year |  |
Jallow, 2009 [31] | 145 [65–210] | NR | NR | NR | NR | NR | NR | NR |
Gottlieb, 2009 [23] | 200 [12–562] | NR | NR | NR | NR | NR | NR | NR |
Harries, 2010 [17] | 111 [31–171] | NR | NR | NR | NR | NR | NR | Means CD4 count M6 = 255, M12 = 270 |
Drylewicz 2010 [30] | 178 [77–232] | NR | PI 278 [248–307] NNRTIs 268 [175–293] | NR | NR | <3 months NNRTIs: -41 (-123; 40) cells/μl/year | >3 months +8.50 (+5.3; +11.7) cells/μl/year |  |
Smith 2010 [43] | 202 [2–1124] | NR | NR | NR |  |  | +8 [-100; +181] cells/mm3/year | 64% CD4 increase and 37% cd4 decline in follow-up |
Chiara, 2010 [44] | 96 [73–111] (3NRTIs)/PI (114)/78 | 3NRTIs/PI (102)/171 | 3NRTIs/PI (91)/254 | NR | NR | NR | NR | NR |
Peterson 2011 [18] | 140 [50–310] | NR | NR | NR | M6: +120 cells M12: +115 cells M24: +285 cells M36: +280 | NR | NR | NR |
Benard, 2011 [15] | 216 [150–287] PI: 191 [90–275] 3NRTI: 170 [72–275] | NR | PI (327) 3NRTI (191) | NR | NR | <3 months PI: +12 cells/μl/months 3NRTI: +6 cells/μl/months | 3-12 months PI: +76 cells/μl/y 3NRTI: -60 cells/μl/y | > = 200 cells/mm3 PI: +52 cells/μl/y 3NRTI: -99 cells/μl/y |
Peterson K, 2012 [45] | 181 [96–200] | NR | NR | NR | NR | NR | NR | NR |